237 related articles for article (PubMed ID: 15809335)
1. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3.
Umehara T; Fukuda K; Nishikawa F; Kohara M; Hasegawa T; Nishikawa S
J Biochem; 2005 Mar; 137(3):339-47. PubMed ID: 15809335
[TBL] [Abstract][Full Text] [Related]
2. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
[TBL] [Abstract][Full Text] [Related]
3. An RNA ligand inhibits hepatitis C virus NS3 protease and helicase activities.
Fukuda K; Umehara T; Sekiya S; Kunio K; Hasegawa T; Nishikawa S
Biochem Biophys Res Commun; 2004 Dec; 325(3):670-5. PubMed ID: 15541341
[TBL] [Abstract][Full Text] [Related]
4. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
[TBL] [Abstract][Full Text] [Related]
5. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
6. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA.
Kumar PK; Machida K; Urvil PT; Kakiuchi N; Vishnuvardhan D; Shimotohno K; Taira K; Nishikawa S
Virology; 1997 Oct; 237(2):270-82. PubMed ID: 9356339
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hepatitis C virus RNA replicons by peptide aptamers.
Trahtenherts A; Gal-Tanamy M; Zemel R; Bachmatov L; Loewenstein S; Tur-Kaspa R; Benhar I
Antiviral Res; 2008 Mar; 77(3):195-205. PubMed ID: 18243349
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection of RNA aptamers against the HCV NS3 helicase domain.
Nishikawa F; Funaji K; Fukuda K; Nishikawa S
Oligonucleotides; 2004; 14(2):114-29. PubMed ID: 15294075
[TBL] [Abstract][Full Text] [Related]
9. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
10. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.
Hwang B; Cho JS; Yeo HJ; Kim JH; Chung KM; Han K; Jang SK; Lee SW
RNA; 2004 Aug; 10(8):1277-90. PubMed ID: 15247433
[TBL] [Abstract][Full Text] [Related]
11. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
Liu D; Wang YS; Gesell JJ; Wyss DF
J Mol Biol; 2001 Nov; 314(3):543-61. PubMed ID: 11846566
[TBL] [Abstract][Full Text] [Related]
12. Specific RNA aptamers to NS3 protease domain of hepatitis C virus.
Fukuda K; Vishinuvardhan D; Sekiya S; Kakiuchi N; Shimotohno K; Kumar PK; Nishikawa S
Nucleic Acids Symp Ser; 1997; (37):237-8. PubMed ID: 9586087
[TBL] [Abstract][Full Text] [Related]
13. Construction of the dual-functional RNA ligand against HCV NS3 protease and helicase.
Fukuda K; Sekiya S; Kikuchi K; Funaji K; Kuno A; Hasegawa T; Nishikawa S
Nucleic Acids Res Suppl; 2001; (1):147-8. PubMed ID: 12836307
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A.
Kuang WF; Lin YC; Jean F; Huang YW; Tai CL; Chen DS; Chen PJ; Hwang LH
Biochem Biophys Res Commun; 2004 Apr; 317(1):211-7. PubMed ID: 15047170
[TBL] [Abstract][Full Text] [Related]
16. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
[TBL] [Abstract][Full Text] [Related]
17. A review of HCV protease inhibitors.
Chen KX; Njoroge FG
Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
[TBL] [Abstract][Full Text] [Related]
18. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
19. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
[TBL] [Abstract][Full Text] [Related]
20. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
